Literature DB >> 10959711

Acquired von Willebrand syndrome: data from an international registry.

A B Federici1, J H Rand, P Bucciarelli, U Budde, P J van Genderen, H Mohri, D Meyer, F Rodeghiero, J E Sadler.   

Abstract

The acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder with laboratory findings similar to those of congenital von Willebrand disease (vWD). Despite the numerous cases reported in the literature until 1999 (n = 266), large studies on AvWS are not available. Moreover, diagnosis of AvWS has been difficult and treatment empirical. These considerations prompted us to organize an international registry. A questionnaire, devised to collect specific information on AvWS, was sent to all the members of the International Society on Thrombosis and Haemostasis (ISTH), who were invited to respond if they had diagnosed cases with the AvWS cases. 156 members answered the questionnaire and 54 of them sent information on 211 AvWS cases from 50 centers. Data were compared with those already published in the literature and 25 cases already described or not correctly diagnosed were excluded. The 186 AvWS cases that qualified for the registry were associated with lymphoproliferative (48%) and myeloproliferative disorders (15%), neoplasia (5%), immunological (2%), cardiovascular (21%) and miscellaneous disorders (9%). Ristocetin cofactor activity (vWF:RCo) or collagen binding activity (vWF:CBA) were usually low in AvWS (median values 20 U/dL, range 3-150), while factor VIII coagulant activity was sometimes normal (median 25 U/dL, range 3-191). FVIII/vWF inhibiting activities were present in only a minority of cases (16%). Bleeding episodes in AvWS were mostly of mucocutaneous type (68%) and were managed by DDAVP (32%), FVIII/vWF concentrates (37%), intravenous immunoglobulins (33%), plasmapheresis (19%), corticosteroids (19%) and immunosuppressive or chemotherapic agents (35%). Based upon the data of this international registry, it appears that AvWS is especially frequent in lympho- or myeloproliferative and cardiovascular diseases. Therefore, AvWS should be suspected and searched with the appropriate laboratory tests especially when excessive bleeding occurs in patients with these disorders. On the basis of the information provided by this registry guidelines for diagnosis and management of the AvWS are given.

Entities:  

Mesh:

Year:  2000        PMID: 10959711

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  48 in total

1.  Acquired von Willebrand syndrome in children with patent ductus arteriosus.

Authors:  R Rauch; U Budde; A Koch; M Girisch; M Hofbeck
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

2.  Are intravenous immunoglobulins really inappropriate in acquired von Willebrand syndrome?

Authors:  Augusto B Federici; Valentina Rossi; Elisabetta Sacchi; Massimo Franchini
Journal:  Blood Transfus       Date:  2012-12-22       Impact factor: 3.443

3.  Type 2B-like acquired von Willebrand syndrome.

Authors:  Toshio Shigekiyo; Etsuko Sekimoto; Atsuhisa Shirakami; Hiroshi Yamaguchi; Hironobu Shibata; Shuji Ozaki; Kazuya Kanda; Seiya Saito; Nobuo Satake; Osamu Fujino
Journal:  Int J Hematol       Date:  2011-09-30       Impact factor: 2.490

Review 4.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

5.  Reversal of angiodysplasia-derived anemia after transcatheter aortic valve implantation.

Authors:  Stylianos A Pyxaras; Sara Santangelo; Andrea Perkan; Giancarlo Vitrella; Serena Rakar; Erica Della Grazia; Alessandro Salvi; Gianfranco Sinagra
Journal:  J Cardiol Cases       Date:  2012-03-16

6.  The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Hagai Amsalem; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

7.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.

Authors:  Massimo Franchini; Giancarlo Castaman; Antonio Coppola; Cristina Santoro; Ezio Zanon; Giovanni Di Minno; Massimo Morfini; Elena Santagostino; Angiola Rocino
Journal:  Blood Transfus       Date:  2015-06-24       Impact factor: 3.443

Review 8.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

9.  Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition.

Authors:  M L Avila; K-J Lee; V Bouskill; M L Rand; P James; M Carcao
Journal:  Haemophilia       Date:  2014-12-11       Impact factor: 4.287

10.  Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.

Authors:  Geoffrey Spencer Chilvers; Graham Porter
Journal:  BMJ Case Rep       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.